<DOC>
	<DOCNO>NCT00816361</DOCNO>
	<brief_summary>Evaluate safety tolerability MEDI-573 adult subject advance solid tumor refractory standard therapy standard therapy exist .</brief_summary>
	<brief_title>A Dose-escalation Study Evaluate Safety , Tolerability , Antitumor Activity MEDI-573 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically confirm advanced solid tumor curative standard therapy exist . Karnofsky Performance Status ≥60 . Adequate hematological function . Adequate organ function . Women nonchildbearing potential ( define &gt; 1 year postmenopausal ) use effective contraception , e.g. , use oral contraceptive additional barrier method ( since investigational product may impair effectiveness oral contraceptive ) , double barrier method ( diaphragm spermicidal gel condom contraceptive foam ) , DepoProvera , partner vasectomy , total abstinence , time informed consent sign 30 day last dose MEDI573 . Male subject partner childbearing potential must surgically sterile use contraceptive method describe time initiation MEDI573 30 day last dose MEDI573 . No prior treatment within 4 week study drug administration . No concurrent therapy treatment cancer . No uncontrolled diabetes . New York Heart Association Grade ≥ 2 congestive heart failure . History myocardial infarction , unstable angina , transient ischemic attack stroke within previous 6 month prior study entry . Documented brain metastasis . Pregnancy lactation plan become pregnant study . Clinically significant abnormality ECG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>